# The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

> **NCT03659136** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 103 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Xentuzumab
- **DRUG:** Placebo
- **DRUG:** Everolimus
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT03659136
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-28
- **Primary completion:** 2021-08-30
- **Final completion:** 2022-05-11
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03659136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03659136, "The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03659136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*